Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 9.12
NRCIA's Cash-to-Debt is ranked higher than
57% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. NRCIA: 9.12 )
Ranked among companies with meaningful Cash-to-Debt only.
NRCIA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 2.12 Max: No Debt
Current: 9.12
Equity-to-Asset 0.69
NRCIA's Equity-to-Asset is ranked higher than
68% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NRCIA: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
NRCIA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.67 Max: 0.8
Current: 0.69
0.51
0.8
Interest Coverage 163.34
NRCIA's Interest Coverage is ranked higher than
57% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. NRCIA: 163.34 )
Ranked among companies with meaningful Interest Coverage only.
NRCIA' s Interest Coverage Range Over the Past 10 Years
Min: 23.53  Med: 52.24 Max: 164.19
Current: 163.34
23.53
164.19
Piotroski F-Score: 8
Altman Z-Score: 11.32
Beneish M-Score: -2.55
WACC vs ROIC
2.16%
38.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 28.52
NRCIA's Operating Margin % is ranked higher than
96% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. NRCIA: 28.52 )
Ranked among companies with meaningful Operating Margin % only.
NRCIA' s Operating Margin % Range Over the Past 10 Years
Min: 21.86  Med: 25.29 Max: 28.63
Current: 28.52
21.86
28.63
Net Margin % 18.45
NRCIA's Net Margin % is ranked higher than
95% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NRCIA: 18.45 )
Ranked among companies with meaningful Net Margin % only.
NRCIA' s Net Margin % Range Over the Past 10 Years
Min: 13.41  Med: 15.99 Max: 18.76
Current: 18.45
13.41
18.76
ROE % 25.61
NRCIA's ROE % is ranked higher than
91% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. NRCIA: 25.61 )
Ranked among companies with meaningful ROE % only.
NRCIA' s ROE % Range Over the Past 10 Years
Min: 17.31  Med: 21.98 Max: 26.84
Current: 25.61
17.31
26.84
ROA % 16.74
NRCIA's ROA % is ranked higher than
94% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NRCIA: 16.74 )
Ranked among companies with meaningful ROA % only.
NRCIA' s ROA % Range Over the Past 10 Years
Min: 10.1  Med: 12.72 Max: 16.74
Current: 16.74
10.1
16.74
ROC (Joel Greenblatt) % 271.66
NRCIA's ROC (Joel Greenblatt) % is ranked higher than
98% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NRCIA: 271.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NRCIA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 94.26  Med: 154.01 Max: 275.14
Current: 271.66
94.26
275.14
3-Year Revenue Growth Rate 5.50
NRCIA's 3-Year Revenue Growth Rate is ranked higher than
58% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. NRCIA: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NRCIA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.3  Med: 11.2 Max: 19.8
Current: 5.5
-16.3
19.8
3-Year EBITDA Growth Rate 7.50
NRCIA's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. NRCIA: 7.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NRCIA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -17  Med: 12.9 Max: 44.1
Current: 7.5
-17
44.1
3-Year EPS without NRI Growth Rate 9.70
NRCIA's 3-Year EPS without NRI Growth Rate is ranked higher than
64% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. NRCIA: 9.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NRCIA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -16.7  Med: 13.8 Max: 58.7
Current: 9.7
-16.7
58.7
GuruFocus has detected 3 Warning Signs with National Research Corp $NRCIA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NRCIA's 10-Y Financials

Financials (Next Earnings Date: 2017-05-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NRCIA Guru Trades in Q1 2016

Jim Simons 72,900 sh (+18.92%)
Chuck Royce 40,033 sh (unchged)
» More
Q2 2016

NRCIA Guru Trades in Q2 2016

Jim Simons 101,800 sh (+39.64%)
Chuck Royce 40,033 sh (unchged)
» More
Q3 2016

NRCIA Guru Trades in Q3 2016

Jim Simons 108,689 sh (+6.77%)
Chuck Royce 40,033 sh (unchged)
» More
Q4 2016

NRCIA Guru Trades in Q4 2016

Jim Simons 127,200 sh (+17.03%)
Chuck Royce 40,033 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NRCIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621399    SIC: 8099
Compare:NYSE:ARA, NAS:VIVO, NAS:NTRA, NAS:LNTH, NAS:NEO, NAS:NVDQ, NYSE:NVTA, NAS:HSKA, NAS:QDEL, NAS:OXFD, NYSE:ENZ, NAS:ONVO, NAS:SRDX, NAS:BEAT, NAS:RDNT, NAS:MGEN, NAS:FLGT, NAS:QTNT, OTCPK:CBIS, NAS:TTOO » details
National Research Corp implements surveys and performs analysis. Its subscription-based solutions provide actionable information and analysis to healthcare organizations.

National Research Corp is a Wisconsin corporation, founded in 1981. The Company implements surveys and performs analysis that recognize a provider's strengths and problem areas, and then uses the data to design specific, measurable improvement strategies. The Company's portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company partners with clients across the continuum of healthcare services. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The two segments, organized by geographic area, are National Research Corporation (United States) and National Research Corporation Canada, which each offer a portfolio of solutions to address specific market needs around growth, retention, engagement and thought leadership for healthcare organizations. The Company's primary competitors among such specialty firms include Press Ganey. The Company competes with traditional market research firms which are significant providers of survey-based, general market research and firms which provide services or products that complement healthcare performance assessments such as healthcare software or information systems.

Top Ranked Articles about National Research Corp

Backtesting Feature Identifies Top-Performing Strategies New feature insight: high dividend yields offer strong portfolio returns
GuruFocus launched the new Backtesting feature within the All-in-One Guru Screener on June 20, allowing users to model an investing strategy’s performance relative to the Standard & Poor’s 500 index, one of the most commonly used benchmarks. Read more...

Ratios

vs
industry
vs
history
PE Ratio 13.99
NRCIA's PE Ratio is ranked higher than
86% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.02 vs. NRCIA: 13.99 )
Ranked among companies with meaningful PE Ratio only.
NRCIA' s PE Ratio Range Over the Past 10 Years
Min: 2.19  Med: 3.85 Max: 18.88
Current: 13.99
2.19
18.88
PE Ratio without NRI 13.99
NRCIA's PE Ratio without NRI is ranked higher than
86% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. NRCIA: 13.99 )
Ranked among companies with meaningful PE Ratio without NRI only.
NRCIA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.19  Med: 3.85 Max: 18.88
Current: 13.99
2.19
18.88
Price-to-Owner-Earnings 12.50
NRCIA's Price-to-Owner-Earnings is ranked higher than
90% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.06 vs. NRCIA: 12.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NRCIA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.42  Med: 3.36 Max: 20.92
Current: 12.5
1.42
20.92
PB Ratio 11.78
NRCIA's PB Ratio is ranked lower than
90% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.55 vs. NRCIA: 11.78 )
Ranked among companies with meaningful PB Ratio only.
NRCIA' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.7 Max: 16.24
Current: 11.78
0.42
16.24
PS Ratio 2.56
NRCIA's PS Ratio is ranked higher than
56% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. NRCIA: 2.56 )
Ranked among companies with meaningful PS Ratio only.
NRCIA' s PS Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.59 Max: 3.3
Current: 2.56
0.32
3.3
Price-to-Free-Cash-Flow 12.29
NRCIA's Price-to-Free-Cash-Flow is ranked higher than
81% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. NRCIA: 12.29 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NRCIA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.44  Med: 3.22 Max: 16.3
Current: 12.29
1.44
16.3
Price-to-Operating-Cash-Flow 10.49
NRCIA's Price-to-Operating-Cash-Flow is ranked higher than
78% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.21 vs. NRCIA: 10.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NRCIA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.23  Med: 2.78 Max: 14.48
Current: 10.49
1.23
14.48
EV-to-EBIT 16.13
NRCIA's EV-to-EBIT is ranked higher than
68% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. NRCIA: 16.13 )
Ranked among companies with meaningful EV-to-EBIT only.
NRCIA' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.3  Med: 2.8 Max: 16.58
Current: 16.13
1.3
16.58
EV-to-EBITDA 14.23
NRCIA's EV-to-EBITDA is ranked higher than
56% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.84 vs. NRCIA: 14.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
NRCIA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.1  Med: 2.3 Max: 14.63
Current: 14.23
1.1
14.63
Shiller PE Ratio 13.51
NRCIA's Shiller PE Ratio is ranked higher than
93% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.56 vs. NRCIA: 13.51 )
Ranked among companies with meaningful Shiller PE Ratio only.
NRCIA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.49  Med: 6.47 Max: 16.41
Current: 13.51
3.49
16.41
Current Ratio 1.49
NRCIA's Current Ratio is ranked lower than
75% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. NRCIA: 1.49 )
Ranked among companies with meaningful Current Ratio only.
NRCIA' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.52 Max: 5.21
Current: 1.49
0.49
5.21
Quick Ratio 1.49
NRCIA's Quick Ratio is ranked lower than
68% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. NRCIA: 1.49 )
Ranked among companies with meaningful Quick Ratio only.
NRCIA' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.52 Max: 5.21
Current: 1.49
0.49
5.21
Days Sales Outstanding 36.25
NRCIA's Days Sales Outstanding is ranked higher than
84% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. NRCIA: 36.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
NRCIA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.97  Med: 45.13 Max: 57.87
Current: 36.25
29.97
57.87
Days Payable 6.13
NRCIA's Days Payable is ranked lower than
95% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. NRCIA: 6.13 )
Ranked among companies with meaningful Days Payable only.
NRCIA' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 8.15 Max: 184.63
Current: 6.13
3
184.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.79
NRCIA's Dividend Yield % is ranked higher than
91% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. NRCIA: 1.79 )
Ranked among companies with meaningful Dividend Yield % only.
NRCIA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.94  Med: 12.68 Max: 23.19
Current: 1.79
0.94
23.19
Dividend Payout Ratio 0.12
NRCIA's Dividend Payout Ratio is ranked higher than
88% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.25 vs. NRCIA: 0.12 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NRCIA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.51 Max: 0.7
Current: 0.12
0.12
0.7
3-Year Dividend Growth Rate 48.70
NRCIA's 3-Year Dividend Growth Rate is ranked higher than
90% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.30 vs. NRCIA: 48.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NRCIA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: -41.1 Max: 48.7
Current: 48.7
0
48.7
Forward Dividend Yield % 2.09
NRCIA's Forward Dividend Yield % is ranked higher than
95% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. NRCIA: 2.09 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.63
NRCIA's 5-Year Yield-on-Cost % is ranked higher than
81% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. NRCIA: 1.63 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NRCIA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.85  Med: 11.52 Max: 21.07
Current: 1.63
0.85
21.07
3-Year Average Share Buyback Ratio -0.30
NRCIA's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. NRCIA: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NRCIA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -93.8  Med: -0.1 Max: 1.9
Current: -0.3
-93.8
1.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 105.56
NRCIA's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.22 vs. NRCIA: 105.56 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NRCIA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.39  Med: 1.51 Max: 716.4
Current: 105.56
0.39
716.4
Price-to-Tangible-Book 45.24
NRCIA's Price-to-Tangible-Book is ranked lower than
96% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.72 vs. NRCIA: 45.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NRCIA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.25  Med: 0.75 Max: 90.16
Current: 45.24
0.25
90.16
Price-to-Intrinsic-Value-Projected-FCF 1.13
NRCIA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. NRCIA: 1.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NRCIA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.12  Med: 0.23 Max: 1.22
Current: 1.13
0.12
1.22
Price-to-Median-PS-Value 4.36
NRCIA's Price-to-Median-PS-Value is ranked lower than
97% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. NRCIA: 4.36 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NRCIA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.9 Max: 4.55
Current: 4.36
0.37
4.55
Price-to-Graham-Number 5.26
NRCIA's Price-to-Graham-Number is ranked lower than
73% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.91 vs. NRCIA: 5.26 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NRCIA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.13  Med: 0.37 Max: 7.94
Current: 5.26
0.13
7.94
Earnings Yield (Greenblatt) % 6.17
NRCIA's Earnings Yield (Greenblatt) % is ranked higher than
85% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. NRCIA: 6.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NRCIA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.03  Med: 35.1 Max: 78
Current: 6.17
6.03
78
Forward Rate of Return (Yacktman) % -2.72
NRCIA's Forward Rate of Return (Yacktman) % is ranked lower than
79% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. NRCIA: -2.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NRCIA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.1  Med: 38 Max: 65
Current: -2.72
-3.1
65

More Statistics

Revenue (TTM) (Mil) $109.4
EPS (TTM) $ 2.85
Beta1.70
Short Percentage of Float0.91%
52-Week Range $12.53 - 20.15
Shares Outstanding (Mil)24.45

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.93
EPS without NRI ($) 0.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.00%
Dividends per Share ($)
» More Articles for NRCIA

Headlines

Articles On GuruFocus.com
Backtesting Feature Identifies Top-Performing Strategies Aug 31 2016 
Meridian Funds Comments on National Research Corp Jun 20 2014 
My 4 Favorite Stocks From The Undervalued Predictable Screener Oct 11 2013 
Four Predictable, Undervalued Stocks Held by Billionaire Investors Sep 22 2013 
13 Not Expensive Stocks with Dividend Yields Over 3% as Well as a Consistent Business Sep 10 2013 
4 Really Undervalued Stocks With High Quality Dividends And A Consistent Business Sep 02 2013 

More From Other Websites
National Research Corp. :NRCIA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Mar 16 2017
NATIONAL RESEARCH CORP Financials Mar 09 2017
NATIONAL RESEARCH CORP Files SEC form 10-K, Annual Report Mar 03 2017
National Research Corp. :NRCIA-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017
Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus... Feb 22 2017
NATIONAL RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 21 2017
National Research posts 4Q profit Feb 14 2017
National Research posts 4Q profit Feb 14 2017
National Research posts 4Q profit Feb 14 2017
National Research Corporation Announces Fourth Quarter and Year-End 2016 Results Feb 14 2017
National Research Corporation to Broadcast its 2016 Fourth Quarter and Year-End Conference Call Live... Feb 03 2017
National Research Corp. breached its 50 day moving average in a Bearish Manner : NRCIA-US : January... Jan 24 2017
Hedge Funds Are Selling First Foundation Inc (FFWM) Dec 14 2016
National Research Corporation, Now NRC Health, Launches Real-time Feedback Solution Alongside New... Dec 05 2016
National Research Corp. breached its 50 day moving average in a Bullish Manner : NRCIA-US : November... Nov 09 2016
National Research Corporation Announces 21st Annual Consumer Choice Award Winners and Advent of New... Nov 07 2016
NATIONAL RESEARCH CORP Files SEC form 10-Q, Quarterly Report Nov 04 2016
National Research Corp. :NRCIA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 Nov 03 2016
NATIONAL RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 02 2016
Impressive Profit Growth At National Research Nov 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)